Table 4 The distribution of patients according to the additional injections required during the week 12 to week 48
Treatment | Between 12 and 16Â weeks | Between 20 and 24Â weeks | Between 28 and 32Â weeks | Between 36 and 40Â weeks | Between 44 and 48Â weeks |
|---|---|---|---|---|---|
Brolucizumab (n = 56) | 3 (5.4%) | 17 (30.4%) | 3 (5.4%) | 1 (1.8%) | 2 (3.6%) |
Aflibercept (n = 58) | 23 (39.7%) | 21 (36.2%) | 13 (22.4%) | 12 (20.7%) | 8 (13.8%) |